Forging Gene Therapy Capacity and a Pipeline at the Same Time
Tim Miller, co-founder and CEO of Forge Biologics, discusses the company’s hybrid business model, how it hopes to differentiate itself through its shared experience with its customers, and its emerging pipeline of gene therapies to treat rare diseases.